Triheptanoin in acute mouse seizure models

Epilepsy Research

Volumn 99, Issue 3, 2012, Pages 312-317

  Thomas, Nicola K ^a   Willis, Sarah ^b   Sweetman, Lawrence ^c   Borges, Karin ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

6Hz; Anaplerosis; Maximal electroshock; Metabolism; Mouse seizure models

Indexed keywords

FLUROTHYL; HEPTANOIC ACID DERIVATIVE; PENTETRAZOLE; PROPIONYLCARNITINE; TRIHEPTANOIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN METABOLISM; CALORIC INTAKE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ELECTROENCEPHALOGRAM; ELECTROSTIMULATION; FOOD INTAKE; LATENT PERIOD; MALE; MOUSE; NONHUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; NUTRITIONAL VALUE; PRIORITY JOURNAL; SEIZURE; SEIZURE THRESHOLD; STANDARDIZATION; THERAPY EFFECT;

ACUTE DISEASE; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C3H; PENTYLENETETRAZOLE; SEIZURES; TRIGLYCERIDES;

EID: 84860496458     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2011.12.013     Document Type: Article

References (23)

1. Alvestad S., Hammer J., Eyjolfsson E., Qu H., Ottersen O.P., Sonnewald U. Limbic structures show altered glial-neuronal metabolism in the chronic phase of kainate induced epilepsy. Neurochem. Res. 2008, 33:257-266.
2. Borges K. Mouse models: the ketogenic diet and polyunsaturated fatty acids. Epilepsia 2008, 49(Suppl 8):64-66.
3. Borges K., Sonnewald U. Triheptanoin-A medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?. Epilepsy Res. 2011, 10.1016/j.eplepsyres.2011.05.023.
4. Broer S., Schneider H.P., Broer A., Rahman B., Hamprecht B., Deitmer J.W. Characterization of the monocarboxylate transporter 1 expressed in Xenopus laevis oocytes by changes in cytosolic pH. Biochem. J. 1998, 333:167-174.
5. Brunengraber H., Roe C.R. Anaplerotic molecules: current and future. J. Inherit. Metab. Dis. 2006, 29:327-331.
6. Giardina W.J., Gasior M. Acute seizure tests in epilepsy research:electroshock and chemical induced convulsions in the mouse. Curr. Protoc. Pharmacol. 2009, 1:5.22.21-25.22.37.
7. Hartman A.L., Gasior M., Vining E.P., Rogawski M.A. The neuropharmacology of the ketogenic diet. Pediatr. Neurol. 2007, 36:281-292.
8. Kimball A.W., Burnett W.T., Doherty D.G. Chemical protection against ionizing radiation. I: Sampling methods for screening compounds in radiation protection studies in mice. Radiat. Res. 1957, 7:1-12.
9. Martini W.Z., Stanley W.C., Huang H., Rosiers C.D., Hoppel C.L., Brunengraber H. Quantitative assessment of anaplerosis from propionate in pig heart in vivo. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E351-E356.
10. Matagne A., Margineanu D.G., Kenda B., Michel P., Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 2008, 154:1662-1671.
11. Melo T.M., Nehlig A., Sonnewald U. Metabolism is normal in astrocytes in chronically epileptic rats: a (13)C NMR study of neuronal-glial interactions in a model of temporal lobe epilepsy. J. Cereb. Blood Flow Metab. 2005, 25:1254-1264.
12. Nakazawa M., Kodama S., Matsuo T. Effects of ketogenic diet on electroconvulsive threshold and brain contents of adenosine nucleotides. Brain Dev. 1983, 5:375-380.
13. Rashed M.S., Bucknall M.P., Little D., Awad A., Jacob M., Alamoudi M., Alwattar M., Ozand P.T. Screening blood spots for inborn errors of metabolism by electrospray tandem mass spectrometry with a microplate batch process and a computer algorithm for automated flagging of abnormal profiles. Clin. Chem. 1997, 43:1129-1141.
14. Reszko A.E., Kasumov T., Pierce B.A., David F., Hoppel C.L., Stanley W.C., Des Rosiers C., Brunengraber H. Assessing the reversibility of the anaplerotic reactions of the propionyl-CoA pathway in heart and liver. J. Biol. Chem. 2003, 278:34959-34965.
15. Roe C.R., Sweetman L., Roe D.S., David F., Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J. Clin. Invest. 2002, 110:259-269.
16. Roe C.R., Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J. Inherit. Metab. Dis. 2006, 29:332-340.
17. Roe C.R., Yang B.Z., Brunengraber H., Roe D.S., Wallace M., Garritson B.K. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 2008, 71:260-264.
18. Roe C.R., Bottiglieri T., Wallace M., Arning E., Martin A. Adult polyglucosan body disease (APBD): anaplerotic diet therapy (Triheptanoin) and demonstration of defective methylation pathways. Mol. Genet. Metab. 2010, 101:246-252.
19. Samala R., Willis S., Borges K. Anticonvulsant profile of a balanced ketogenic diet in acute mouse seizure models. Epilepsy Res. 2008, 81:119-127.
20. Smith M., Wilcox K.S., White H.S. Discovery of antiepileptic drugs. Neurotherapeutics 2007, 4:12-17.
21. Silver J.M., Shin C., McNamara C.J.O. Antiepileptogenic effects of conventional anticonvulsants in the kindling model of epilespy. Ann. Neurol. 1991, 29:356-363.
22. White H.S Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia 2003, 44(Suppl 7):2-8.
23. Willis S., Stoll J., Sweetman L., Borges K. Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. Neurobiol. Dis. 2010, 40:565-572.